{"id":552497,"date":"2025-11-06T08:10:13","date_gmt":"2025-11-06T08:10:13","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/552497\/"},"modified":"2025-11-06T08:10:13","modified_gmt":"2025-11-06T08:10:13","slug":"glp-1-goliath-updates-demand-for-top-weight-loss-drug","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/552497\/","title":{"rendered":"GLP-1 goliath updates demand for top weight loss drug"},"content":{"rendered":"\n

Novo Nordisk reported Q3 2025 earnings<\/a> on November 5, showing continued strong demand for its weight-loss drug Wegovy, despite rising costs and pricing pressure forcing the company to narrow its full-year guidance.<\/p>\n

The drugmaker reported a 15% increase in U.S. sales at Constant Exchange Rates (CER) in the first nine months of 2025, with operating profit increasing 10% to Danish Kroner (DKK) 95.9 billion ($14.7 billion).<\/p>\n

If one-time restructuring charges of approximately DKK 9 billion were excluded, the operating profit would have increased by 21%.<\/p>\n

Free cash flow decreased to DKK 63.9 billion from DKK 71.8 billion in 2024, and the company announced DKK 53 billion in shareholder returns, primarily through dividend payments.<\/p>\n

Obesity care growth, led by Wegovy, surged 41% to DKK 59.9 billion, while GLP-1 diabetes treatments grew 10%, with sales of rare disease treatments increasing 13%.<\/p>\n

Despite the strong results, the company’s stock was down 3.9%, marking a 45% year-to-date decline.<\/p>\n

\"<em>Novo Novo Nordisk’s stock reported a 45% year-to-date decline.Getty <\/p>\n

Novo Nordisk stated that the obesity segment accounts for the bulk of its growth, with a global GLP-1 market share of 59%.<\/p>\n

Yet, the company trimmed its full-year guidance, suggesting lower growth expectations for GLP-1 amid rising competition and pricing pressure in the U.S. market.<\/p>\n

Now, the company has announced FDA\u2019s approval of Wegovy for the treatment of MASH (Metabolic Dysfunction-Associated Steatohepatitis)<\/strong>, a form of fatty-liver disease that can lead to liver failure.<\/p>\n

The approval opens a new potential market for Wegovy, strengthening Novo Nordisk\u2019s long-term growth prospects.<\/p>\n

More Health Care:<\/strong><\/p>\n

In addition, Novo Nordisk agreed to acquire biotech Akero Therapeutics <\/strong>and its Phase 3 drug, an FGF21 analogue,<\/strong> for the treatment of MASH.<\/p>\n

Bringing Wegovy and Akero together could give Nordisk a commanding position in the emerging market for metabolic liver diseases.<\/p>\n